🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being viewed as a "major milestone" in the battle against increasingly resistant strains of the infection, according to health experts.

A Worldwide Public Health Issue

The sexually transmitted infection are escalating worldwide, with estimates suggesting over 82 million new cases annually. Notably increased rates are observed in the African continent and countries within the World Health Organization's designated area, which includes Mongolia and China to New Zealand. In England, cases have hit a all-time high, while figures across Europe in 2023 were three times higher compared to figures for 2014.

“The authorization of novel therapies for gonorrhoea is an important and timely step in the face of rising global incidence, increasing antimicrobial resistance and the extremely scarce available drugs presently on offer.”

Health officials are increasingly worried about the surge in treatment-resistant strains. The WHO has listed it as a "priority pathogen". A tracking program revealed that resistance to primary antibiotics like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Two New Therapies Secure Authorization

One new antibiotic, marketed under the name Nuzolvence, was approved by the American regulatory agency in mid-December for treating gonorrhoea. This infection can lead to significant complications, including infertility. Scientists believe that specific application of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, originating from the pharmaceutical company GSK, was also approved in the same week. This medication, which is additionally indicated for UTIs, was proven in research to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Partnership

This new treatment stemmed from a new, not-for-profit approach for medication research. The charitable organization GARDP partnered with the pharmaceutical company its industry partner to see it through.

“This authorization marks a huge turning point in the therapy of superbug gonorrhoea, which up to this point has been staying ahead of medical innovation.”

Clinical Trial Data and Worldwide Availability

Based on results detailed in a major medical journal, the new drug eradicated the vast majority of genital gonorrhoea infections. This establishes an comparable level with the typical regimen, which combines an injection and a pill. The research included hundreds of volunteers from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, the non-profit has the ability to license and sell the drug in numerous regions with limited resources.

Doctors on the front lines have voiced hope. Access to a one-pill regimen like this is described as a "game-changer" for public health efforts. This is deemed crucial to lessen the impact of the disease for patients and to stop the proliferation of highly drug-resistant gonorrhoea worldwide.